Clearmind completes recruitment for first AUD cohort in CMND‑100 Phase I/IIa trial
+1 new source since this summary was written
Clearmind Medicine announced that it has finished enrolling patients for the initial segment of Part B of its Phase I/IIa study of CMND‑100 in individuals with moderate‑to‑severe alcohol use disorder. The segment comprises two single‑dose cohorts, one at 80 mg and another at 160 mg, each enrolling six participants. The study is being run at major clinical sites in the United States and Israel, including hospitals in Baltimore, New Haven, Tel Aviv and Jerusalem.
Why it matters
The recruitment milestone enables the company to begin generating safety, tolerability and early efficacy data in the target patient population, a key step before advancing the program to later‑stage trials. Investors will watch the upcoming data to assess the therapeutic potential of CMND‑100.
Key facts
- 1Recruitment was completed for the first segment of Part B of the Phase I/IIa CMND‑100 trial in moderate‑to‑severe alcohol use disorder patients. stocktitan.net
- 2The segment consists of two single‑dose ascending cohorts of 80 mg and 160 mg, each enrolling six patients. stocktitan.net
- 3A total of 12 patients will be treated in this segment. investing.com
- 4Trial sites include leading hospitals in the United States and Israel, such as facilities in Baltimore, New Haven, Tel Aviv and Jerusalem. stocktitan.net
- 5CEO Dr. Adi Zuloff‑Shani said the recruitment milestone moves the program from healthy volunteers to the target patient group. stocktitan.net
Summary written by AlphAI AI Desk from 3 of 3 sources. Not investment advice. Figures are as stated by the linked sources.